China-based global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) announced on Wednesday that it has named Xu Wang as its new chief executive officer (CEO).
Wang succeeds Dave Chenn and Dr Hui Shao, who has stepped down from the company's interim CEO and co-CEO positions, respectively.
Wang has worked as the firm's chief operation officer since June 2024, and will no longer assume such role upon becoming the company's chief executive officer.
Gavi signs agreement with Bavarian Nordic for Mpox vaccines
Valneva seeks label extensions for chikungunya vaccine in Europe and Canada
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Pfizer names new Regional President for Middle East, Russia and Africa
LakeShore Biopharma names new chief executive officer
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Bavarian Nordic secures additional USD156.8m US government contract